Scientific Sessions

Session 1: Vitreoretinal Techniques

Friday 18 May
09.30-10.30

Chairperson:	S. Binder AUSTRIA
Moderator:	G. Ripandelli ITALY
09.30	P. Kroll GERMANY The role of the posterior hyaloid in different vitreo-retinal diseases
09.42	P. Brazitikos GREECE Evolving techniques in 25-gauge vitrectomy
09.54	J.F. Korobelnik FRANCE 25 Gauge surgery: do we still need it?
10.06	S. Binder AUSTRIA What so we lose and gain with 25 - and 23 - gauge instruments for pars plane vitrectomy
10.18	A. Gandorfer GERMANY Pharmacologic vitreolysis: Results from the MIVI trials
10.30	End of session

Session 2: Treatment of Macular Disorders

Friday 18 May
11.00-13.00

Chairperson:	G. Richard GERMANY
Moderator:	A. Kampik GERMANY
11.00	A. Kampik GERMANY Ultrastructural findings in idiopathic and recurrent macular holes
11.12	F. Bottoni ITALY Differential diagnosis of pseudo/lamellar macular holes with fundus autofluorescence
11.24	G. Ripandelli ITALY Asymptomatic macular holes in high myopic eyes
11.36	R. Tadayoni FRANCE Macular holes: relationship between the size and the prognosis
11.48	A. Laidlaw UK ICG assisted ILM peeling: friend or foe?
12.00	N. Lois UK FILMS (Full thickness macular hole and Internal Limiting Membrane peeling study)
12.12	F. Cardillo-Piccolino ITALY Long-term outcomes of photodynamic therapy in central serous chorioretinopathy
12.24	S. Chang USA Does triamcinolone assisted membrane peeling improve the outcomes of macular pucker?
12.36	C. Mateo SPAIN Myopic macula: Implications for treatment
12.48	R. MacLaren UK Technical aspects relating to photoreceptor transplantation
13.00	End of session

Session 3: Imaging and Functional Analysis

Friday 18 May
11.00-13.00

Chairperson:	R. Brancato ITALY
Moderator:	F. Holz GERMANY
11.00	C. Azzolini ITALY How to improve the diagnostic power of OCT imaging
11.12	L. Chong USA High resolution OCT, adaptive optics scanning laser ophthalmoscopy
11.24	G. Virgili ITALY Optical coherence tomography versus stereoscopic fundus photography or biomicroscopy for diagnosing diabetic macular edema: a systematic review
11.36	W. Drexler UK Cellular resolution and functional OCT
11.48	A. Hassenstein GERMANY The clinical relevance of the new digital integration method (DIM) for the precise correlation of FLA and OCT findings
12.00	F. Holz GERMANY New perspectives in fundus autofluorescence imaging in AMD
12.12	J. Sahel FRANCE Photoreceptor imaging in retinal degenerations
12.24	P. De Potter BELGIUM Role of imaging studies in intraocular tumors and simulating lesions
12.36	B. Falsini ITALY Retinal flicker responsiveness in age-related maculopathy: spatial and temporal aspects
12:48	E. Stefánsson ICELAND Noninvasive Retinal Oximetry
13.00	End of session

Session 4: Update on Uveitis

Saturday 19 May
09.30-10.30

Chairperson:	A. Adan SPAIN
Moderator:	B. Kuppermann USA
09.30	B. Kuppermann USA Pharmacokinetics of ocular drug delivery systems and their clinical implications
09.42	B. Bodaghi FRANCE Diagnosis and management of herpetic retinopathies
09.54	P. Le Hoang FRANCE Management of herpetic retinopathies
10.06	A. Adan SPAIN Vitreous surgery for pars planitis: indications and long term follow-up
10.18	A. Giovannini ITALY Management of inflammatory CNV
10.30	End of session

Session 5: New Therapies for ARMD

Saturday 19 May
11.00-13.00 

Chairperson:	J. Mones SPAIN
Moderator:	S. Wolf SWITZERLAND
11.00	J.M. Rakic BELGIUM Mechanisms of choroidal neovascularization and biological grounds for AMD treatments
11.12	W. Mieler USA AMD Update 2007
11.24	M. Mauget-Fa˙sse FRANCE Choroidal neovascularization management in AMD in 2007
11.36	J. Mones SPAIN Update on Ranibizumab
11.48	M. Varano ITALY Functional and morphological evaluation after treatment with Ranibizumab for neovascular age-related macular degeneration
12.00	S. Wolf SWITZERLAND Combination therapy for exudative ARMD. short term effects
12.12	A. Augustin GERMANY New combination approaches for the treatment of wet AMD (triple therapy)
12.24	G. Richard GERMANY Long-term results after transplantation of HLA-typed RPE cells in geographic atrophy
12.36	G. Staurenghi ITALY Dye enhanced photocoagulation of feeder vessels
12.48	U. Introini ITALY From PDT to antiangiogenic therapy in vascularized pigment epithelium detachments
13.00	End of session

Session 6: Gene Therapy - "From Bench to Bedside"

Saturday 19 May
16.30-18.30 

Chairperson:	R. Ali UK
Moderator:	A. Auricchio ITALY
16.30	R. Ali UK Introduction to gene therapy
16.45	A. Auricchio ITALY AAV vectors for retinal gene therapy
17.04	K. Balaggan UK Lentiviral vectors for retinal gene therapy
17.21	J. Farrar IRELAND Gene therapy for dominant forms retinitis pigmentosa
17.38	J. Wijnholds NETHERLANDS Gene therapy for LCA caused by CRB1 gene defects
17.55	Y. Arsenijevic SWITZERLAND Gene therapy for LCA caused by RPE65 gene defects
18.12	J. Bainbridge UK Towards clinical applications of gene therapy
18.30	End of session

Session 7 : Update on Heavy Silicone Oils

Saturday 19 May
16.30-18.30 

Chairperson:	D. Wong UK
Moderator:	Y. LeMer FRANCE
16.30	D. Wong UK An introduction to Heavy Tamponade and the HSO study
16.39	T. Stappler UK An audit of a consecutive series
16.48	F. Devin FRANCE Heavy silicon oil tamponade, what you need to know
16.57	M. Oncel TURKEY Heavy silicone oil in the management of complicated retinal detachment
17.06	J. Van Meurs NETHERLANDS The use of Densiron in RPE patch graft
17.15	S. Rizzo ITALY The use of Densiron for persistent macular hole
17.24	P. Tomlins UK Whats in your oil? An analysis of Oxane Hd
17.33	M. Tilanus NETHERLANDS A randomised trial of Densiron and Oxane Hd
17.42	S. Rizzo ITALY The use of Densiron for persistent macular hole
17.51	R. Williams UK High molecular weight Silicone oil
18.00	N. Kociok GERMANY Newer Heavy Silicone Oils
18.09	Discussion
18.30	End of session

Session 8 : Retinal Detachment

Sunday 20 May
08.00 – 10.00 

Chairperson:	J. Van Meurs NETHERLANDS
Moderator:	J. Pastor SPAIN
08.00	G. Lewis USA Pathogenic mechanisms in experimental retinal detachment: cellular proliferation, gliosis, and PVR
08.12	S. Fisher USA Neuronal remodelling after experimental retinal detachment: implications for the return of vision
08.24	J. Pastor SPAIN Genetic approach of PVR
08.36	T. Wolfensberger SWITZERLAND Prophylaxis of retinal detachment
08.48	M. Feucht GERMANY Rhegmatogenous retinal detachment: more rules to find the break
09.00	H. Heimann GERMANY Results of the "Scleral buckling versus primary vitrectomy in rhegmatogenous retinal detachment study (SPR study)"
09.12	M. Tilanus NETHERLANDS "Buckle is alive": indication and results of external RD surgery
09.24	V. Martinez-Castillo SPAIN Vitrectomy for retinal detachment - is tamponade really necessary?
09.36	P. Nucci ITALY Retinochoroidal colobomata: an overview
09.48	M. Stirpe ITALY Influence of vitreoretinal modifications on RD after uneventful cataract surgery in emmetropic eyes
10.00	End of session

Session 9 : Paediatric Retina

Sunday 20 May
09.30 – 10.30 

Chairperson:	A. Deutman NETHERLANDS
Moderator:	E. Silva PORTUGAL
09.30	G. Caputo FRANCE Surgery in advanced stages of rop
09.42	A. Kychenthal CHILE 25-gauge Vitrectomy in Retinopathy of Prematurity
09.54	B. Leroy BELGIUM Leber Congenital Amaurosis: Novel Insights
10.06	E. Silva PORTUGAL The hairy tale of Bardet Biedl Syndrome
10.30	End of session

Session 10 : Vascular & Diabetic Eye Disease

Sunday 20 May
11.00 – 13.00 

Chairperson:	J. Cunha-Vaz PORTUGAL
Moderator:	P. Massin FRANCE
11.00	T. Gardner USA Why do people with diabetes lose vision?
11.12	E. Midena ITALY Visual loss in diabetic retinopathy: neural vascular interactions
11.24	J. Garcia-Arumi SPAIN The role of erythropoietin in diabetic retinopathy
11.36	J. Cunha-Vaz PORTUGAL Options for treatment of Diabetic Macular Edema
11.48	P. Massin FRANCE New treatment modalities for diabetic macular edema
12.00	C. Haritoglou GERMANY Anti-VEGF therapy for diabetic macular edema (prospective study)
12.12	M. Paques FRANCE CRVO revealed by transient acute ischemia: long-term follow-up
12.24	S. Priglinger GERMANY Anti-VEGF-therapy in retinal venous occlusive disease
12.36	O. Zeitz GERMANY Hemodynamic effects of radial optic neurotomy
12.48	Y. Le Mer FRANCE Vein cannulation for the treatment of CRVO
13.00	End of session